Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Fig. 2

OAK and POPLAR cohort were used to evaluate association of bTMB and PD-L1 expression with EPHA5 mutation. This is a flow chart(A). Comparison of mutation count, TMB between EPHA5-mutated and wild-type tumors (P < 0.0001) (B). The difference of positive and strong positive PD-L1 expression between EPHA5-mutated and non. PD-L1 had higher proportion in non-mutant cohort compared with that in EPHA5-mutated one (56.2 vs. 46.0, P = 0.1634 and 17.6 vs. 15.7, P = 0.7333) (C). PD-L1: programmed death ligand 1; bTMB: blood tumor mutation burden

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us